8-K: Healthcare Trust, Inc. Announces Estimated Per-Share Net Asset Value of $13.00

Healthcare Trust, Inc. has set its estimated per-share net asset value at $13.00 as of December 31, 2023, based on independent appraisals and board review.

Summary

• Healthcare Trust, Inc.'s board of directors has approved an estimated per-share net asset value (NAV) of $13.00 as of December 31, 2023.
• This valuation was determined by the independent directors of the board, based on input from the company's advisor and an independent valuation firm, Kroll, LLC.
• Kroll provided a valuation range, and the $13.00 NAV fell within that range.
• The NAV calculation considers the fair value of the company's real estate assets, other assets, liabilities, and the liquidation value of preferred stock, divided by the number of common shares outstanding.
• The company's common stock outstanding as of December 31, 2023 was 112,034,251 shares.
• The NAV was influenced by a stock dividend issued in January 2024 and the estimated sale prices of three properties expected to be sold after December 31, 2023.
• A sensitivity analysis showed that the NAV could range from $12.01 to $13.60 per share, depending on capitalization and discount rates.
• The company engaged Kroll for the past nine years to assist in determining the company's estimated per-share NAV.
• Kroll used various valuation methods, including the Direct Capitalization Method, Discounted Cash Flow Method, Sales Comparison Approach, Acquisition Method, and Disposition Method.
• The company's real estate assets were valued using a combination of these methods, with the Discounted Cash Flow Method being used for 177 properties and the Direct Capitalization Method for 15 properties.
• The weighted average capitalization rate used was 6.71%, and the weighted average discount rate was 8.31%.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's estimated NAV. While the NAV is within the expected range, there are risks and limitations associated with the valuation, which tempers the overall sentiment.

Positives

• The independent directors of the board unanimously approved the $13.00 per share NAV.
• The NAV was determined using a well-established valuation process with an independent third-party firm.
• The company has engaged Kroll for the past nine years, indicating a consistent approach to valuation.
• The valuation methodology complies with industry guidelines and professional standards.
• The company provided a sensitivity analysis showing a range of potential values, offering transparency.

Negatives

• The estimated NAV does not represent the price at which shares would trade on a national exchange.
• The NAV does not reflect a liquidity discount for the fact that the shares are not publicly traded.
• The NAV is based on estimates and assumptions that may not be accurate or complete.
• The NAV does not reflect enterprise value, which may include a premium for a large portfolio or intangible value.
• The company has not paid distributions on its common stock in cash since 2020, and there is no assurance it will in the future.

Risks

• The company's operating results are affected by economic and regulatory changes in the real estate market.
• The company's property portfolio is concentrated in Florida and Pennsylvania, exposing it to regional economic risks.
• The company's real estate investments are concentrated in healthcare-related facilities, which may be negatively impacted by adverse trends in the healthcare industry.
• The company depends on its advisor and property manager, and any adverse changes to their financial health or reputation could impact the company.
• Conflicts of interest may arise due to the involvement of the company's executive officers and directors in related entities.
• The company's debt level may increase its business risks.
• The company's financing arrangements have restrictive covenants that may limit its ability to pursue strategic alternatives.
• There is no public market for the company's common stock, and it may remain illiquid.
• The company's failure to remain qualified as a REIT would subject it to U.S. federal income tax.
• The company's share ownership restrictions may inhibit market activity in its shares of stock and restrict its business combination opportunities.

Future Outlook

The company's estimated per-share NAV will likely change over time due to changes in the value of individual assets, real estate and capital markets, and interest rates. The company disclaims any obligation to update forward-looking statements unless required by law.

Management Comments

• The independent directors of the Board based their conclusions on their review of the Advisors analysis and recommendation, the Kroll Report, estimates and calculations and the fundamentals of the Real Estate Assets.
• The Board is ultimately and solely responsible for the Estimated Per-Share NAV.

Industry Context

This announcement is typical for non-traded REITs, which are required to provide periodic updates on their estimated per-share NAV. The valuation process is complex and involves independent appraisals and board oversight. The use of various valuation methods, such as discounted cash flow and direct capitalization, is standard practice in the commercial real estate industry.

Comparison to Industry Standards

• The valuation process used by Healthcare Trust, Inc. is consistent with industry standards for non-traded REITs, which typically engage independent valuation firms to determine their NAV.
• The use of Kroll, a well-known real estate advisory firm, is comparable to other non-traded REITs that use similar firms for valuations.
• The company's disclosure of the valuation methodology, including the use of discounted cash flow and direct capitalization methods, is in line with industry best practices.
• The sensitivity analysis provided by the company, showing the impact of varying capitalization and discount rates, is a common practice to provide transparency to investors.
• The company's disclosure of the limitations of the NAV, including the fact that it does not represent a trading price or liquidation value, is also consistent with industry standards.

Stakeholder Impact

• Shareholders will be informed of the company's estimated per-share NAV.
• The NAV provides a benchmark for the value of the company's common stock.
• The NAV is used for financial reporting and compliance purposes.

Next Steps

• The company will continue to monitor the value of its assets and liabilities.
• The board will determine a new estimated per-share NAV in the future.
• The company will continue to provide updates to its investors.

Key Dates

Keywords

Net Asset Value, NAV, Real Estate, Valuation, Healthcare Trust, Kroll, Preferred Stock, REIT, Commercial Real Estate, Discounted Cash Flow, Direct Capitalization